Pregnancy outcome after treatment with the ergot derivative, cabergoline

Reproductive Toxicology

Volumn 10, Issue 4, 1996, Pages 333-337

  Robert, Elisabeth ^a   Musatti, Lisa ^b   Piscitelli, Gabriella ^b   Ferrari, Carlo I ^c  

^a Institut Europeen des Genomutations   (France)

^b PFIZER INC   (United States)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

cabergoline; pregnancy

Indexed keywords

ANIMALIA; ORYCTOLAGUS CUNICULUS; POMACANTHUS MACULOSUS;

EID: 0030197564     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/0890-6238(96)00063-9     Document Type: Article

References (17)

1. 1. Beltrame D, Longo M, Mazué G. Cabergoline, animal reproductive toxicity. Reprod Toxicol. (submitted).
2. 2. Stormshak F, Zelinski-Wooten MB, Abdelgadir SE. Comparative aspects of the regulation of corpus luteum function in various species. Adv Exp Med Biol. 1987;219:327-60.
3. 3. The study group of hyperprolactinemia. Survey of infants born to mothers treated with bromocriptine. 8th study group meeting, Osaka, 1985 (Unpublished).
4. 4. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247:1589-91.
5. 5. Krupp P, Monka P. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65:823-7.
6. 6. Ferrari C, Piscitelli G, Crosignani PG. Cabergoline: a new drug for the treatment of hyperprolactinemia. Hum Reprod. 1995;10:101-7.
7. 7. Webster J, PisciteHi G, Polli A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol. 1993; 39:323-9.
8. 8. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative in hyperprolactinemic patients, J Clin Endocrinol Metab. 1989;69:725-8.
9. 9. Ferrari C, Paracchi A, Mattel AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. 1992;126:489-94.
10. 10. Grottoli S, Ciccarelli E, Miola C, et al. Efficacy and tolerability of chronic therapy with cabergoline in patients with hyperprolactinemia. J Endocrinol Invest. 1991;14(Suppl 1):104.
11. 11. Tamburrano G, Jafrain-Rea ML, Bulletta C, et al. Cabergoline and bromocriptine-induced pregnancies in women with nonoperated microprolactinomas. J Endocrinol Invest. 1991;14(Suppl 1):104.
12. 12. Jones TH, Fraser RB. Cabergoline-treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. Br J Obstet Gynaecol. 1994;101:349-50.
13. 13. Hammerslough CR. Estimating the probability of spontaneous abortion in the presence of induced abortion and vice versa. Public Health Rep. 1992;107:269-77.
14. 14. Laferla JJ. Spontaneous abortion. Clin Obstet Gynecol. 1986; 13: 105-14.
15. 15. Källén, B. Epidemiology of human reproduction. Boca Raton, FL: CRC; 1988.
16. 16. Mastroiacovo P, Källén B, Knudsen LB, Lancaster AL, Castilla EE, Mutchinick O, Robert E. Absence of limbs and gross body wall defects - an epidemiological study of related rare malformation conditions. Teratology. 1992;46:455-64.
17. 17. Rall TW. Oxytocin, prostaglandins, ergot alkaloids and other drugs; tocolytic agents. In Goodman LS, Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's: the pharmacological basis of therapeutics. 3th ed. New York: Pergamon Press Inc.; 1991.